Latest Capital Raising News

Breakthrough Minerals has completed its acquisition of the high-grade Errolls Gold Project in Western Australia and raised A$1.2 million to fund an imminent drilling campaign targeting promising gold lodes.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Miramar Resources has announced a $1 million Share Purchase Plan to fast-track drilling at its promising 8 Mile gold prospect near Kalgoorlie, following recent significant mineralisation discoveries.

Nordic Resources has completed a major acquisition of three advanced gold projects in Finland, lifting its total gold equivalent resources to 1.23 million ounces. The company also secured A$3.5 million in institutional funding and appointed a seasoned mining executive as Chairman.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Prodigy Gold NL has lodged a replacement Appendix 3Y to amend the reported securities held by Managing Director Mark Edwards following his participation in the company’s recent Entitlement Offer.

Norwest Minerals has reported a substantial 33% increase in its Bulgera Gold Project resource to 288,400 ounces and secured $4.85 million to advance exploration, including a new drilling campaign targeting deeper gold zones.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

Alternative Investment Trust (ASX, AIQ) announces a special unfranked distribution of AUD 0.04647 per unit, representing a full return of capital payable in early August.

ikeGPS Limited has completed a significant placement of ordinary shares, issuing over 22 million new shares at NZD 0.88 each, representing nearly 14% of its total shares post-issue. The placement prioritized existing shareholders and aims to strengthen the company’s share register.

Macarthur Minerals has extended the timetable for its A$2 million renounceable rights issue, providing shareholders additional time to participate amid ongoing regulatory scrutiny by ASIC. The company confirms no changes to the offer terms and expects to lodge an updated Supplementary Prospectus shortly.

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.